logo
logo
SNDX stock ticker logo

Syndax Pharmaceuticals, Inc.

NASDAQ•SNDX
CEO: Mr. Michael A. Metzger M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2016-03-02
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Contact Information
35 Gatehouse Drive, Building D Floor 3, Waltham, MA, 02451, United States
781-419-1400
www.syndax.com
Market Cap
$1.86B
P/E (TTM)
-6.5
19.9
Dividend Yield
--
52W High
$22.73
52W Low
$8.58
52W Range
91%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$68.48M+0.00%
4-Quarter Trend

EPS

-$0.78+0.00%
4-Quarter Trend

FCF

-$69.54M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Massive Revenue Surge Total revenue reached $172.35M in 2025, up 627.8% from $23.68M in 2024, driven by product sales.
Product Revenue Established Net product revenue hit $124.84M in 2025, up from $7.68M in 2024, following Revuforj U.S. launch.
Collaboration Revenue Streams Collaboration revenue, net, totaled $42.37M in 2025 from Niktimvo co-commercialization with Incyte partner.
Net Loss Narrowed Net loss improved by $33.34M to $285.42M in 2025, reflecting initial commercial revenue impact.

Risk Factors

Commercialization Execution Risk Success heavily depends on successful U.S. commercialization of Revuforj and Niktimvo; no guarantee of expected revenue timing.
High Operating Expense R&D expenses were $258.78M in 2025; SG&A rose $58.80M supporting new product launches.
Continued Net Losses Company incurred net losses since inception (except 2021); anticipates continued losses for the near future.
Intellectual Property Defense Success depends on maintaining patent rights; litigation risk exists regarding owned and licensed IP portfolios.

Outlook

Advance Revumenib Pipeline Continue advancing Revumenib frontline trials in combination therapies for NPM1m and KMT2Ar AML indications.
Expand Niktimvo Indications Advance clinical development for Niktimvo in newly diagnosed cGVHD patients and explore IPF treatment proof-of-concept.
Strategic Partner Leverage Leverage expertise with Incyte for axatilimab and seek external partners for U.S. Revuforj commercialization evaluation.
Future Funding Requirements Future capital needs depend on growth rate, trial costs, and regulatory outcomes; potential dilution if financing secured.

Peer Comparison

Revenue (TTM)

SNDX stock ticker logoSNDX
$172.35M
+627.8%
IMTX stock ticker logoIMTX
$93.54M
-26.7%
SYRE stock ticker logoSYRE
$90.49M
+0.0%

Gross Margin (Latest Quarter)

SNDX stock ticker logoSNDX
102.3%
-13.9pp
IMTX stock ticker logoIMTX
100.0%
+0.0pp
ATAI stock ticker logoATAI
100.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRAX$6.73B-23.6-58.7%0.0%
WVE$2.50B-11.8-85.7%2.8%
SYRE$2.42B-89.3-29.4%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
50.6%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 4, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data